Responsiveness of patients with advanced ovarian carcinoma to tamoxifen

A Gynecologic Oncology Group study of second-line therapy in 105 patients

Kenneth D Hatch, J. B. Beecham, J. A. Blessing, W. T. Creasman

Research output: Contribution to journalArticle

203 Citations (Scopus)

Abstract

One hundred five patients with Stage III or IV epithelial ovarian cancer whose disease had persisted or recurred after primary surgery and first-line chemotherapy were given tamoxifen (20 mg orally twice daily) and evaluated for response. Eighteen percent of the patients responded: 10% demonstrated a complete response (CR) and 8% showed a partial response (PR). Thirty-eight percent of the patients had short-term disease stabilization. CR had a median duration of 7.5 months, with the longest lasting 17 months. For patients with PR or stable disease, the median duration of response was 3 months (maximum duration, 9 months). When estrogen receptors of tumor tissue from patients demonstrating CR were evaluated, eight of nine (89%) had elevated estrogen receptor levels. This contrasts with patients who had stable or progressive disease as only 59% of them had measurable estrogen receptors (P = 0.16).

Original languageEnglish (US)
Pages (from-to)269-271
Number of pages3
JournalCancer
Volume68
Issue number2
DOIs
StatePublished - 1991

Fingerprint

Tamoxifen
Carcinoma
Estrogen Receptors
Therapeutics
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Responsiveness of patients with advanced ovarian carcinoma to tamoxifen : A Gynecologic Oncology Group study of second-line therapy in 105 patients. / Hatch, Kenneth D; Beecham, J. B.; Blessing, J. A.; Creasman, W. T.

In: Cancer, Vol. 68, No. 2, 1991, p. 269-271.

Research output: Contribution to journalArticle

@article{d5f779d1538a47b08d912822a59aa32e,
title = "Responsiveness of patients with advanced ovarian carcinoma to tamoxifen: A Gynecologic Oncology Group study of second-line therapy in 105 patients",
abstract = "One hundred five patients with Stage III or IV epithelial ovarian cancer whose disease had persisted or recurred after primary surgery and first-line chemotherapy were given tamoxifen (20 mg orally twice daily) and evaluated for response. Eighteen percent of the patients responded: 10{\%} demonstrated a complete response (CR) and 8{\%} showed a partial response (PR). Thirty-eight percent of the patients had short-term disease stabilization. CR had a median duration of 7.5 months, with the longest lasting 17 months. For patients with PR or stable disease, the median duration of response was 3 months (maximum duration, 9 months). When estrogen receptors of tumor tissue from patients demonstrating CR were evaluated, eight of nine (89{\%}) had elevated estrogen receptor levels. This contrasts with patients who had stable or progressive disease as only 59{\%} of them had measurable estrogen receptors (P = 0.16).",
author = "Hatch, {Kenneth D} and Beecham, {J. B.} and Blessing, {J. A.} and Creasman, {W. T.}",
year = "1991",
doi = "10.1002/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO;2-O",
language = "English (US)",
volume = "68",
pages = "269--271",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Responsiveness of patients with advanced ovarian carcinoma to tamoxifen

T2 - A Gynecologic Oncology Group study of second-line therapy in 105 patients

AU - Hatch, Kenneth D

AU - Beecham, J. B.

AU - Blessing, J. A.

AU - Creasman, W. T.

PY - 1991

Y1 - 1991

N2 - One hundred five patients with Stage III or IV epithelial ovarian cancer whose disease had persisted or recurred after primary surgery and first-line chemotherapy were given tamoxifen (20 mg orally twice daily) and evaluated for response. Eighteen percent of the patients responded: 10% demonstrated a complete response (CR) and 8% showed a partial response (PR). Thirty-eight percent of the patients had short-term disease stabilization. CR had a median duration of 7.5 months, with the longest lasting 17 months. For patients with PR or stable disease, the median duration of response was 3 months (maximum duration, 9 months). When estrogen receptors of tumor tissue from patients demonstrating CR were evaluated, eight of nine (89%) had elevated estrogen receptor levels. This contrasts with patients who had stable or progressive disease as only 59% of them had measurable estrogen receptors (P = 0.16).

AB - One hundred five patients with Stage III or IV epithelial ovarian cancer whose disease had persisted or recurred after primary surgery and first-line chemotherapy were given tamoxifen (20 mg orally twice daily) and evaluated for response. Eighteen percent of the patients responded: 10% demonstrated a complete response (CR) and 8% showed a partial response (PR). Thirty-eight percent of the patients had short-term disease stabilization. CR had a median duration of 7.5 months, with the longest lasting 17 months. For patients with PR or stable disease, the median duration of response was 3 months (maximum duration, 9 months). When estrogen receptors of tumor tissue from patients demonstrating CR were evaluated, eight of nine (89%) had elevated estrogen receptor levels. This contrasts with patients who had stable or progressive disease as only 59% of them had measurable estrogen receptors (P = 0.16).

UR - http://www.scopus.com/inward/record.url?scp=0025935370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025935370&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO;2-O

DO - 10.1002/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO;2-O

M3 - Article

VL - 68

SP - 269

EP - 271

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -